Friday, November 12, 2010
Monday, November 8, 2010
Plavix Lawsuit
Plavix Lawsuit Filed Over Heart Attacks and Strokes Suffered by 11 People
Published: November 8th, 2010 • http://www.aboutlawsuits.com
Nearly a dozen people who allege that they suffered a heart attack, stroke or other serious injury as a result of side effects of Plavix, a popular blood thinner, have filed a product liability lawsuit against Bristol-Myers Squibb and Sanofi Aventis, alleging that the drug makers exaggerated claims about the effectiveness of Plavix and failed to adequately warn about the risks associated with the medication.
The Plavix lawsuit was filed in St. Clair County Circuit Court in Illinois by 11 plaintiffs from across the United States, all of whom say that the drug makers failed to warn them of Plavix health risks and falsely promoted the drug as safer and more effective than it actually was. According to a report in The St. Clair Record, the complaint alleges that plaintiffs suffered heart attacks, strokes, bleeding and cardiovascular complications that resulted in physical disfigurements, impairment, pain and suffering.
Plavix (clopidogrel) is a blood thinner that prevents blood platelets from sticking together to form clots. It is prescribed to prevent heart attacks, strokes and blood clotting when drug coated stents are used in patients with arteriosclerosis and in other at-risk patients. It is a blockbuster medication, generating annual sales of over $9 billion for Bristol Myers Squibb Co. and Sanofi-Aventis.
The lawsuit alleges that the Plavix makers promoted the expensive medication as a safer alternative to aspirin, although it may actually provides no benefits over taking aspirin alone and could actually increase the risk of heart attacks, strokes, gastrointestinal bleeding, severe ulcers and a rare blood disorder known as TTP, or thrombotic thrombocytopenic purpora.
Similar allegations have been raised in other Plavix lawsuits that have been filed on behalf of individuals throughout the country, including several dozen that are pending in the U.S. District Court for the District of New Jersey. In addition, previous reports suggest that there are thousands of other cases that are likely to be filed.
Tags: Aspirin, Blood Thinner, Gastrointestinal Bleeding, Heart Attack, Illinois, New Jersey, Plavix, Product Liability, Sanofi-Aventis, Stroke, Supreme Court
Published: November 8th, 2010 • http://www.aboutlawsuits.com
Nearly a dozen people who allege that they suffered a heart attack, stroke or other serious injury as a result of side effects of Plavix, a popular blood thinner, have filed a product liability lawsuit against Bristol-Myers Squibb and Sanofi Aventis, alleging that the drug makers exaggerated claims about the effectiveness of Plavix and failed to adequately warn about the risks associated with the medication.
The Plavix lawsuit was filed in St. Clair County Circuit Court in Illinois by 11 plaintiffs from across the United States, all of whom say that the drug makers failed to warn them of Plavix health risks and falsely promoted the drug as safer and more effective than it actually was. According to a report in The St. Clair Record, the complaint alleges that plaintiffs suffered heart attacks, strokes, bleeding and cardiovascular complications that resulted in physical disfigurements, impairment, pain and suffering.
Plavix (clopidogrel) is a blood thinner that prevents blood platelets from sticking together to form clots. It is prescribed to prevent heart attacks, strokes and blood clotting when drug coated stents are used in patients with arteriosclerosis and in other at-risk patients. It is a blockbuster medication, generating annual sales of over $9 billion for Bristol Myers Squibb Co. and Sanofi-Aventis.
The lawsuit alleges that the Plavix makers promoted the expensive medication as a safer alternative to aspirin, although it may actually provides no benefits over taking aspirin alone and could actually increase the risk of heart attacks, strokes, gastrointestinal bleeding, severe ulcers and a rare blood disorder known as TTP, or thrombotic thrombocytopenic purpora.
Similar allegations have been raised in other Plavix lawsuits that have been filed on behalf of individuals throughout the country, including several dozen that are pending in the U.S. District Court for the District of New Jersey. In addition, previous reports suggest that there are thousands of other cases that are likely to be filed.
Tags: Aspirin, Blood Thinner, Gastrointestinal Bleeding, Heart Attack, Illinois, New Jersey, Plavix, Product Liability, Sanofi-Aventis, Stroke, Supreme Court
Nephrogenic Systemic Fibrosis
Nephrogenic Systemic Fibrosis (NSF) Lawsuit Set For Trial January 2011
Published: November 8th, 2010 http://www.aboutlawsuits.com
Trial has been schedule to begin early next year for a lawsuit involving allegations that a gadolinium-based MRI contrast agent led to the development of nephrogenic systemic fibrosis (NSF), a severe and debilitating injury.
The trial could be the first NSF lawsuit to reach a jury out of hundreds of complaints filed against manufacturers of gadolinium contrast agents in the United States. A number of settlements have reportedly been reached in other cases that were being prepared for trial.
According to an order issued by U.S. District Judge Dan A. Polster, who is presiding over pretrial litigation for all federal lawsuits over nephrogenic systemic fibrosis from MRI contrast agents, trial will begin on January 24, 2011 in a case filed by Loralei and Donald Knase against GE Healthcare over its Omniscan MRI contrasting agent.
The case was originally selected as the third bellwether trial, which are designed to help the parties gauge how juries will respond to evidence that is likely to be similar to what would be offered in other cases pending in the MDL.
Lorelei Knase was given Omniscan several times between March 2003 and October 2005 for enhanced MRI scans, according to the complaint. The gadolinium-based contrast agent is used to help improve the images obtained from an MRI, but Knase alleges that neither she nor her physicians were warned about the potential side effects of Omniscan, which have been linked to an increased risk of nephrogenic systemic fibrosis.
Knase developed NSF following the MRIs and developed fibrosis in her hands, feet, arms, legs, and associated joints. The lawsuit describes the injuries as serious, progressive, incurable and potentially fatal.
Sometimes referred to as nephrogenic fibrosing dermopathy (NFD), the painful and rare condition that Knase developed is only known to occur after exposure to a gadolinium-based contrast agent (GBCA) among individuals with impaired kidney function. There is no cure for the painful and debilitating disorder, and in many cases it results in death.
Although all types of gadolinium MRI contrast agents have been linked to nephrogenic systemic fibrosis, reports have suggested that the risk of NSF associated with Omniscan may be higher than other with contrast agents.
In 2007, the manufacturers of gadolinium-based contrast agents were required by the FDA to add a “black box” warning to their products, indicating that individuals with severe kidney problems could develop NSF.
Approximately 350 lawsuits over nephrogenic systemic fibrosis have been filed in the United States by individuals who developed the condition after receiving a gadolinium-based contrast agent. Out of the five approved contrast agents, Omniscan has been associated with the most cases of NSF, outnumbering the other drugs in proportions that far exceed their market share. It has been estimated that about 75% of all NSF lawsuits involve cases where the plaintiff developed the condition after use of Omniscan, even though GE’s contrast agent only accounts for about 30% of the market share.
Tags: Bayer, Gadolinium, GE Healthcare, Magnevist, MRI, MRI Contrast Agent, Nephrogenic Fibrosing Dermopathy, Nephrogenic Systemic Fibrosis, NFD, NSF, Omniscan
Published: November 8th, 2010 http://www.aboutlawsuits.com
Trial has been schedule to begin early next year for a lawsuit involving allegations that a gadolinium-based MRI contrast agent led to the development of nephrogenic systemic fibrosis (NSF), a severe and debilitating injury.
The trial could be the first NSF lawsuit to reach a jury out of hundreds of complaints filed against manufacturers of gadolinium contrast agents in the United States. A number of settlements have reportedly been reached in other cases that were being prepared for trial.
According to an order issued by U.S. District Judge Dan A. Polster, who is presiding over pretrial litigation for all federal lawsuits over nephrogenic systemic fibrosis from MRI contrast agents, trial will begin on January 24, 2011 in a case filed by Loralei and Donald Knase against GE Healthcare over its Omniscan MRI contrasting agent.
The case was originally selected as the third bellwether trial, which are designed to help the parties gauge how juries will respond to evidence that is likely to be similar to what would be offered in other cases pending in the MDL.
Lorelei Knase was given Omniscan several times between March 2003 and October 2005 for enhanced MRI scans, according to the complaint. The gadolinium-based contrast agent is used to help improve the images obtained from an MRI, but Knase alleges that neither she nor her physicians were warned about the potential side effects of Omniscan, which have been linked to an increased risk of nephrogenic systemic fibrosis.
Knase developed NSF following the MRIs and developed fibrosis in her hands, feet, arms, legs, and associated joints. The lawsuit describes the injuries as serious, progressive, incurable and potentially fatal.
Sometimes referred to as nephrogenic fibrosing dermopathy (NFD), the painful and rare condition that Knase developed is only known to occur after exposure to a gadolinium-based contrast agent (GBCA) among individuals with impaired kidney function. There is no cure for the painful and debilitating disorder, and in many cases it results in death.
Although all types of gadolinium MRI contrast agents have been linked to nephrogenic systemic fibrosis, reports have suggested that the risk of NSF associated with Omniscan may be higher than other with contrast agents.
In 2007, the manufacturers of gadolinium-based contrast agents were required by the FDA to add a “black box” warning to their products, indicating that individuals with severe kidney problems could develop NSF.
Approximately 350 lawsuits over nephrogenic systemic fibrosis have been filed in the United States by individuals who developed the condition after receiving a gadolinium-based contrast agent. Out of the five approved contrast agents, Omniscan has been associated with the most cases of NSF, outnumbering the other drugs in proportions that far exceed their market share. It has been estimated that about 75% of all NSF lawsuits involve cases where the plaintiff developed the condition after use of Omniscan, even though GE’s contrast agent only accounts for about 30% of the market share.
Tags: Bayer, Gadolinium, GE Healthcare, Magnevist, MRI, MRI Contrast Agent, Nephrogenic Fibrosing Dermopathy, Nephrogenic Systemic Fibrosis, NFD, NSF, Omniscan
Baugher's
Baugher’s Apple Cider Recall Issued Over E. Coli Outbreak in Maryland
Published: November 8th, 2010 • http://www.aboutlawsuits.com
A recall of unpasteuried Baugher’s Apple Cider has been issued following reports of E. coli food poisoning in Maryland, which has caused several people to be hospitalized.
On Thursday the FDA announced the Baugher’s Apple Cider recall after an investigation by the Maryland Department of Health and Mental Hygiene (DHMH) found that seven people in Maryland have been infected with E. coli O157:H7 since October 22.
There have been three reports of hospitalizations and one report of a condition known as Hemolytic-Urenia Syndrome (HUS), a form of kidney failure caused by E. coli poisoning. There have been no deaths reported in relation to the E. coli outbreak.
E. coli O157:H7 is one of the more common causes of food poisoning in the United States. When left untreated, it can lead to dehydration and potentially life-threatening illness. While most healthy adults recover from food poisoning caused by E. coli within a few weeks, young children and the elderly could be at risk for more severe illness. If the toxin enters the blood stream, E. coli could also lead to HUS.
Investigators believe they have tracked the illnesses back to Baugher’s Orchard & Farm’s unpasteurized apple cider. FDA, DHMH and Baugher Enterprise are asking people to discard all Baugher’s Apple Cider. The investigators are currently examining the production facility for the source of the contamination.
Baugher’s Apple Cider is sold in Maryland and Pennsylvania in half-gallon and gallon containers. The recall affects all of the cider on the market.
State and federal health officials recommend that consumers do not drink the cider and dispose of it immediately in a way that prevents both humans and animals from drinking it. No other Baugher’s products are currently affected by the recall.
Tags: Apple, Food Poisoning, Hemolytic Uremic Syndrome, Kidney Failure, Maryland, Pennsylvania
Published: November 8th, 2010 • http://www.aboutlawsuits.com
A recall of unpasteuried Baugher’s Apple Cider has been issued following reports of E. coli food poisoning in Maryland, which has caused several people to be hospitalized.
On Thursday the FDA announced the Baugher’s Apple Cider recall after an investigation by the Maryland Department of Health and Mental Hygiene (DHMH) found that seven people in Maryland have been infected with E. coli O157:H7 since October 22.
There have been three reports of hospitalizations and one report of a condition known as Hemolytic-Urenia Syndrome (HUS), a form of kidney failure caused by E. coli poisoning. There have been no deaths reported in relation to the E. coli outbreak.
E. coli O157:H7 is one of the more common causes of food poisoning in the United States. When left untreated, it can lead to dehydration and potentially life-threatening illness. While most healthy adults recover from food poisoning caused by E. coli within a few weeks, young children and the elderly could be at risk for more severe illness. If the toxin enters the blood stream, E. coli could also lead to HUS.
Investigators believe they have tracked the illnesses back to Baugher’s Orchard & Farm’s unpasteurized apple cider. FDA, DHMH and Baugher Enterprise are asking people to discard all Baugher’s Apple Cider. The investigators are currently examining the production facility for the source of the contamination.
Baugher’s Apple Cider is sold in Maryland and Pennsylvania in half-gallon and gallon containers. The recall affects all of the cider on the market.
State and federal health officials recommend that consumers do not drink the cider and dispose of it immediately in a way that prevents both humans and animals from drinking it. No other Baugher’s products are currently affected by the recall.
Tags: Apple, Food Poisoning, Hemolytic Uremic Syndrome, Kidney Failure, Maryland, Pennsylvania
Subscribe to:
Posts (Atom)